Organon & Co. (NYSE:OGN) Hits New 12-Month High - Still a Buy?

Key Points

• Organon reached a new 52-week high of $13.79, trading near $13.78, above its 50-day and 200-day moving averages.
• Analyst sentiment remains cautious: five analysts rate the stock Hold and two rate it Sell, resulting in a consensus “Reduce” rating and a $11.40 target price.
• The company pays a quarterly dividend of $0.02, or $0.08 annually, representing a 0.6% yield; institutional investors own 77.43% of outstanding shares.

Organon & Co. (NYSE:OGN - Get Free Report) reached a new 52-week high during trading on Wednesday. The stock traded as high as $13.79 and last traded at $13.7750, with a volume of 2207764 shares trading hands. The stock had previously closed at $13.74.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of Organon & Co. from a "hold (c)" rating to a "hold (c-)" rating in a report on Monday, August 3rd. Five research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Reduce" and a consensus target price of $11.40.

Organon & Co. Price Performance

The business has a fifty day moving average of $13.70 and a two-hundred day moving average of $12.38. The company has a debt-to-equity ratio of 8.43, a quick ratio of 1.44 and a current ratio of 1.95. The firm has a market capitalization of $3.62 billion, a price-to-earnings ratio of 17.89, a price-to-earnings-growth ratio of 1.27 and a beta of 1.55.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 10th. Shareholders of record on Friday, August 14th were issued a $0.02 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. Organon & Co.'s payout ratio is currently 10.39%.

Institutional Investors Weigh In On Organon & Co.

Several institutional investors have recently made changes to their positions in OGN. Allied Private Wealth LLC bought a new stake in shares of Organon & Co. during the 2nd quarter valued at $33,000. Nykredit A S bought a new stake in Organon & Co. during the second quarter worth about $76,000. GAMMA Investing LLC lifted its position in Organon & Co. by 69.8% during the second quarter. GAMMA Investing LLC now owns 5,782 shares of the company's stock worth $78,000 after purchasing an additional 2,376 shares during the period. Wedmont Private Capital bought a new position in Organon & Co. in the 2nd quarter valued at about $136,000. Finally, WNY Asset Management LLC bought a new position in Organon & Co. in the 1st quarter valued at about $64,000. 77.43% of the stock is currently owned by institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company focused primarily on women's health, biosimilars and a portfolio of established medicines. The company develops, manufactures and commercializes prescription products designed to address a range of health needs, with an emphasis on expanding access to treatments in markets around the world.

Its women's health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines used in areas including fertility and reproductive health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.